Jade Biosciences Inc to Discuss Interim Phase 1 Healthy Volunteer Results Transcript

Jun 01, 2026 / 12:00PM GMT

Release Date Price: $18.59 (-11.64%)

Transcript

Operator

Good morning, and welcome to the Jade Biosciences conference call and webcast to discuss JADE101 Phase I healthy volunteer study results. (Operator Instructions) Now I'd like to turn it over to Tom Frohlich, Chief Executive Officer of Jade Biosciences.

Tom Frohlich

Jade Biosciences Inc - Chief Executive Officer, President and Director

Please go ahead. Thank you, and good morning, everyone. Earlier today, we announced positive interim results from our Phase I trial for JADE101, a potentially best-in-class, fully human monoclonal antibody designed to selectively inhibit a proliferation-inducing flagged or APRIL.

APRIL is a key driver of pathogenic IgA production in patients with IgA nephropathy, a progressive autoimmune kidney disease that presents a lifetime risk of kidney failure. On today's call, we'll walk you through interim results for the Phase I trial for JADE101 and our development plans for this candidate.

Moving to slide 2. Before we begin, I'd like to note that today's discussion will include forward-looking statements. These

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.